$0.36—Stale · unknown old
XETRA • Last print unknown ago
$0.36—Stale · unknown old
Paion AG is a biopharmaceutical company focused on developing and commercializing innovative drugs for anesthesia and sedation. Its lead product, Remimazolam, is a rapid-acting sedative that has received regulatory approval in various markets, including Europe and the U.S., positioning the company to capitalize on the growing demand for procedural sedation.
Paion AG generates revenue primarily through the sale of Remimazolam, leveraging its unique pharmacokinetic profile that allows for rapid onset and offset of sedation. The company benefits from strong pricing power due to the drug's innovative nature and limited competition in the procedural sedation market.
Regulatory approvals for Remimazolam in new markets
Partnership agreements for distribution and commercialization
Clinical trial results for pipeline products
Market adoption rates of Remimazolam among healthcare providers
Regulatory changes impacting drug approval processes
Technological advancements in sedation alternatives
Emergence of generic versions of Remimazolam
Increased competition from other sedatives with similar profiles
High debt-to-equity ratio of 3.08 raises concerns about financial stability
Negative net margins indicate potential liquidity issues if revenue growth does not continue
moderate - The demand for healthcare services, including sedation procedures, is somewhat correlated with GDP growth, as economic conditions can influence elective procedures.
Low - The company is not heavily reliant on debt financing, but rising rates could impact overall market valuations.
minimal - Paion AG's operations are not significantly dependent on credit markets.
growth - Investors are likely attracted to the potential for rapid revenue growth driven by Remimazolam's market penetration.
high - The stock has exhibited high volatility, with a 1-year return of -95.8%, indicating significant market sensitivity.